In-vitro antibacterial activity and cytotoxicity of selected medicinal plant extracts from Penang Island Malaysia on metronidazole-resistant-Helicobacter pylori and some pathogenic bacteria. by Uyub, Abdul M. et al.
  Correspondence
www.ethnobotanyjournal.org/vol8/i1547-3465-08-095.pdf
Ethnobotany Research & Applications 8:095-106 (2010)
Abdul M. Uyub, Ikenna, N. Nwachukwu, Ahmad A. Azlan and 
Shaida S. Fariza, School of Biological Science, Universiti Sains 
Malaysia, 11800, Penang, MALAYSIA.
uyub@usm.my; ikennatex@yahoo.com 
ease Research report shows that two thirds of the world’s 
populations harbor this bacterium, with infection rates 
much higher in developing countries (NCI 2006, Rahman 
et al. 2009). This infection leads to frequent chronic gas-
tritis world wide (Correa & Piazuelo 2008). Helicobacter 
pylori infection in developing countries is characterized 
by rapid rate of acquisition, approximately 80% of the 
population is infected at the age of 20 (Malaty 2007), be-
cause the disease is acquired at child hood (Malaty et 
al. 2002). Moujaber et al. (2008) reported lower preva-
lence rates in Australia (15.4%), than (Everhart et al. 
2000) in the U.S.A. (32.5%). However, there are indica-
tions of declining prevalence of H. pylori in various parts 
of the world, resulting in overlapping prevalence rates in 
the East and West (Leong 2009, Malaty 2007). Correla-
tions have been made between the presence of H. pylori 
and the development of several disease conditions such 
as gastric adenocarcinoma and gastric lymphoma (Rah-
man et al. 2009), pancreatic adenocarcinoma, ischaemic 
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Abstract 
Helicobacter pylori is the major agent in the etiology of 
chronic active gastritis, duodenal and gastric ulcers and 
has been linked to gastric carcinoma. The increasing an-
tibiotic resistance of this organism and other bacteria has 
led to increased treatment failures, especially in therapies 
involving commonly used antibiotics. Malaysia has an un-
explored potential of medicinal plants. This study evalu-
ates the in-vitro antimicrobial activity of 32 selected medic-
inal plants used in Malaysian traditional medicine for gas-
trointestinal disorders and wounds. Extracts were tested 
against H. pylori by disc diffusion and agar dilution meth-
ods. Toxicity of the most potent extracts was also inves-
tigated. Organic solvent extracts of Derris trifoliata Lour. 
selectively inhibited H. pylori, and thus was further stud-
ied. Petroleum ether (PE), chloroform (CHL) and metha-
nol (MET) extracts were tested against 13 other bacterial 
isolates representing eight genera. Petroleum ether and 
chloroform extracts showed strong activity against met-
ronidazole-resistant clinical isolates of H. pylori with MIC90 
and MIC50 ranging from 1- 4mg/l. All extracts of D. trifo-
liata produced higher inhibition zone diameters against H. 
pylori than for other bacteria. Toxicity tests showed Lc50 
of PE, CHL and MET extracts on Artemia salina Leach 
as 1.14, 1.1, and 54.9mg/l respectively. Chemical analy-
sis revealed the presence of fatty acids, steroids, triterpe-
noids, alkaloids, phenols, and phenyl propanoids, tannin, 
and mucilage in the extracts. Derris trifoliata shows poten-
tial as a source of selective anti-H. pylori agent.
Introduction
Isolation of Helicobacter pylori in Australia represented a 
breakthrough in the scientific understanding of peptic ul-
cer disease (Warren & Marshall 1983). A Center for Dis-
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heart and cerebrovascular disease, artherosclerosis and 
skin diseases (Gasbarrini et al. 1997, Pakodi et al. 2000). 
Recently also the relationship between H. pylori and gas-
tric cancer has been proven (Correa & Piazuelo 2008, Fu-
kase et al. 2008). Liou et al. (2008) however reported that 
only 10-15% of infected persons will develop peptic ulcer 
disease while only about 1% of patients will have gastric 
cancer or mucosa associated lymphoid tissue lymphoma.
Despite the high incidence of this infection, the reservoirs 
and transmission pathways to humans are still unclear 
(Quaglia et al. 2008). Some of the most recent literature 
however suggest that transmission of H. pylori occurs 
from person to person, both via the oral-oral and faecal-
oral routes, while others suggest that human infections 
may occur by contaminated foods and water, zoonotically, 
and iatrogenically (Cellini et al. 2001, Delport & Merwe 
2007, Gomes & DeMartinis 2004).
The conventional eradication therapies combine two an-
tibiotics and a proton pump inhibitor (Castillo-Juárez et 
al. 2009). Treatment regimens containing metronidazole, 
clarithromycin and a proton pump inhibitor are amongst 
the most efficacious (De Francesco et al. 2009, Osato et 
al. 1999). The success rate following this therapy is con-
stantly decreasing, mainly due to antibiotic resistance (De 
Boer & Tytgat 2000, Kwon et al. 2001, Wolle & Malferthei-
ner 2007).
Resistance of H. pylori to antibiotics is a growing world 
concern and needs urgent public health attention (Jenks 
& Edwards 2002). The resistance especially to metron-
idazole and amoxicillin limit their use in the treatment of 
H. pylori infections. Reported frequencies of resistance to 
antibiotics used in treatment/eradication of H. pylori vary 
widely with different antibiotics and between geographical 
regions, and even amongst subgroups within a study pop-
ulation. Values vary from about 37.4% for metronidazole 
in U.S.A. (Osato et al. 1999) to about 80-90% in devel-
oping countries (Mégraud 2001). A recent study in Egypt 
(Ragab et al. 2009), reported resistance of H. pylori to 
metronidazole (90%), amoxicillin (88%), clarithromycin 
(20%), tetracycline (11.4%), and ciprofloxacin (7%). A re-
cent research (Salasawati & Ramela 2009), found a high 
level resistance (minimum effective concentration, MIC 
>256mg/l) in 24.5% of clinical isolates of H. pylori to met-
ronidazole in Kualar Lumpur, Malaysia. This problem is 
encountered more in Africa (Ndip et al. 2007), and other 
developing countries. Poor patient compliance, due to un-
desirable side effects of drugs and the significant cost of 
combination therapy clearly reveals the need to seek al-
ternative available means of eradicating or preventing in-
fections (O’Gara et al. 2000).
Currently there has been a resurgence of scientific inter-
est in the use of medicinal plants for the development of 
new pharmaceutical agents. It is estimated that plant ma-
terials as present has provided the models for about 50% 
of western drugs (Harborne 1998) Studies regarding an-
ti-H. pylori activity of medicinal plants have also increased 
considerably in recent times. Phytochemicals may indeed 
serve as an alternative source of materials for H. pylori 
eradication because they constitute a rich source of bio-
chemicals. Many natural substances and plants such as 
ecabet sodium, tea catechins, garlic extracts, honey, Teph-
rosia purpurea (L.) Pers., Tabebuia impetiginosa (Mart. ex 
DC.) Standl. (e.g., Castillo-Juárez et al. 2009, Chinniah et 
al. 2009, Gadhi et al. 2001, Li et al. 2005, Ndip et al. 2007, 
Park et al. 2006), have been shown to possess anti-H. py-
lori activities. However, very high MIC and toxicity values 
have been the major setback confronting the exploitation 
of these findings.
In Malaysia, plant derived medicines have been part of 
the traditional health care for ages, especially against sto-
machic complaints and infection related aliments. Given 
the alarming resistance in a bacterium proven to be the 
etiologic agent of active chronic gastritis, peptic ulcer dis-
ease and gastric cancer amongst other diseases, (Uemu-
ra et al. 2001) the search for cheaper, safer and more ef-
fective anti H. pylori agents is indeed necessary.
This paper reports anti-H. pylori activity of 32 Malaysian 
plants used in Malaysian ethnomedicine for treatment of 
stomach complaints, giving special attention to the organ-
ic solvent extracts of Derris trifoliata Lour. with regard to 
its activity against metronidazole resistant clinical isolates 
of H. pylori, and some common pathogenic and opportu-
nistic pathogenic bacteria. Toxicity and preliminary phy-
tochemical analysis of the extracts are also reported. 
Materials and Methods
Plant selection and preparation of extracts
Thirty-two plants were selected based on ethnobotanical 
information obtained from traditional medicine practitio-
ners in Malaysia. The plants are used for treatment of sto-
machic complaints and cure of wounds or external tissue 
injury. All the plants are commonly found and were col-
lected around Penang Island, Malaysia. Plant vouchers 
were kindly identified and stored by the Botanical Garden, 
Universiti Sains Malaysia, Pulau Pinang Malaysia. Either 
parts or whole plants were used for extraction (Table 1).
Material of each plant was dried at room temperature (28 
±3oC) by exposure to atmosphere. The dried materials 
were pulverized into very fine powder. Ten grams of each 
sample was soxhlet extracted sequentially using Petro-
leum Ether (PE), Chloroform (CHL) (Uemura et al. 2001), 
Methanol (MET) at 60oC, and water at boiling tempera-
ture. The crude extract was vacuum dried, redissolved in 
Dimethyl Sulfoxide (DMSO, Fluka, Swizerland) and finally 
sterilized by filtration (Whatman 0.2µm).
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Table 1. Plants screened for anti-Helicobacter pylori activity. Plants selected based on ethnobotanical information 
obtained from traditional medicine practitioners in Malaysia. 





























Calotropis gigantea (L.) W.T. Aiton X
Centella asiatica (L.) Urb. X
Chromolaena odorata (L.) R.M. King & H. Rob. X
Colubrina asiatica (L.) Brongn. X
Cosmos caudatus Kunth X
Cymbopogon citratus (DC.) Stapf X
Desmos cochinchinensis Lour. X
Derris trifoliata Lour. X
Ficus deltoidea Jack X
Hibiscus rosa-sinensis L. (white variety) X X
Jatropha podagrica Hook. X X X
Kaempferia galanga L. X X
Labisia pumila Benth. & Hook. f X
Languas galanga (L.) Stuntz X
Limnocharis flava (L.) Buchenau X
Melastoma malabathricum L. (blue variety) X X
Mimosa pudica L. X
Mitrasacme alsinoides R. Br. X
Neptunia oleracea Lour. X
Orthosiphon stamineus Benth. X X
Parkia speciosa Hassk. X
Pereskia sacharosa Griseb. X
Phaeomeria imperialis (Roscoe) Lindl. X
Phyllanthus niruri L. X
Piper betle L. X
Pluchea indica (L.) Less. X
Polygonum minus Huds. X
Psidium guajava L. X
Sesbania grandiflora (L.) Pers. X
Solarnum torvum Sw. X
Tinospora cordifolia (Willd.) Miers X
Zingiber officinale Roscoe X
Chemical analysis of extracts
Phytochemical analysis of the extracts was carried out 
according to the methods of the National Pharmaceuti-
cal Control Bureau, Malaysia. PE extract was tested for 
the presence of fat, fatty acids, steroids, terpenoids and 
carotenoids, while the CHL extract was tested for alka-
loids, phenolics, flavonoids, and anthraquinones. MET ex-
tract was tested for alkaloids, glycosides, tannin and mu-
cilage.
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Bacterial cultures
H. pylori were isolated from antral biopsies of patients un-
dergoing routine gastroduodenoscopy for stomach com-
plaints at a hospital in northern peninsular Malaysia. Biop-
sies were transported in Stuart transport medium (Oxoid, 
U.K.), inoculated onto Eugon agar (BBL, U.S.A.) plus 10% 
(v/v) human blood. Incubation was at 37oC under CO2 + 
air atmosphere for 4 days (Uyub & Sasidharan 2000). 
Presence of H. pylori was confirmed by rapid urease test 
and microscopy. H. pylori SJ47 isolated from a 60 year 
old woman was used as a working culture for screening of 
anti-H. pylori activity of plants.
Other pathogenic bacteria such as Enterobacter sp., Es-
cherichia coli ATTC 25922, Escherichia coli, Proteus vul-
garis, Pseudomonas aeruginosa, Pseudomonas stutzeri, 
Salmonella sp., Salmonella paratyphi A, Shigella boydii, 
Shigella dysenteriae, Staphylococcus aureus, Vibrio chol-
erae, and Vibrio parahaemolyticus were obtained from 
Departmental stock cultures, School of Biological Scienc-
es, Universiti Sains Malaysia. They were grown aerobi-
cally on Mueller- Hinton agar (BBL, USA) at 37oC. All bac-
teria were preserved in tryptic soy broth (BBL, U.S.A.) + 
10% (v/v) glycerol at -80oC prior to revival. In each case 
they were revived shortly before antimicrobial assay. 
Screening of plants with anti H. pylori activity
A disc diffusion assay was initially used to screen plants 
for anti-H. pylori activity. Cells were harvested from growth 
medium and turbidity was adjusted to a scale of 0.5 on 
the MacFarland standard (Biomerieux, France). A sterile 
wire swab was immersed into the suspension and rotated 
firmly against the inner wall of the tube to squelch excess 
liquid. The agar surface was then swabbed three times, 
rotating the plates 60 degrees between swabbing to en-
sure even distribution of cells. Disks (AA, 6mm, Whatman 
U.K.) which had been impregnated with 20µl of each ex-
tract was deposited on the agar and gently pressed with 
sterile forceps to ensure complete contact with the agar 
surface. Six disks, two as negative controls (each impreg-
nated with water and DMSO), and the remaining 4, each 
impregnated with PE, CHL, MET, and water extracts were 
used per plate. They were deposited with their centers at 
least 25mm apart.
Activity of D. trifoliata against H. pylori 
and other pathogenic bacteria
 
In subsequent experiments, when only extracts from D. 
trifoliata were studied, extract amounts were standard-
ized at 240µg per disk. The extracts were tested against 
H. pylori SJ47 and 13 other bacteria. Only 4 disks were 
used impregnated with one each of DMSO (as negative 
control), PE, CHL, and MET extracts were deposited per 
plate. Their centers were at least 30mm apart. This test 
was carried out to determine whether the extracts could 
also inhibit other bacteria that could inhabit the gastroin-
testinal tract, whether as pathogens or normal flora. Plates 
inoculated with H. pylori were incubated microaerophili-
cally as described, while plates inoculated with other bac-
teria were incubated aerobically at 37oC.
Toxicity assay using brine shrimps, 
Artemia salina Leach
Cytotoxicity of extracts from D. trifoliata was evaluated in 
triplicate using Artemia salina Leach. Brine shrimp eggs 
(Focus, U.S.A.) were hatched in artificial sea water (Kes-
ter et al. 1967). After 48 hours the phototrophic nauplii 
were collected and a suspension of about 30–50 nauplii 
in 100 µl were placed into bijoux bottles containing 900 
µl of extract in artificial sea water. Eight final concentra-
tions of the extract ranging from 1-128 µg/ml, at two fold 
serial increments were used in the assay. The control bi-
joux bottle contained the nauplii in 1000 µl artificial sea 
water but devoid of the extract. After 24 hours of incu-
bation, the dead nauplii were counted under a dissecting 
microscope. Subsequently 200 µl of methanol was added 
to each bottle and 60 minutes later the total number of 
nauplii were counted. Cytotoxicity, expressed as LC50 was 
calculated using the formula:
Log LC50 – Log Concentration A / Log Concentration B – 
Log Concentration A = 50% - M / N - M 
Where concentration A is the concentration before LC50, 
concentration B is the concentration after LC50, M is the % 
killed before LC50, and N is the % killed after LC50.
Determination of Minimum Inhibitory 
Concentration (MIC)
Minimum Inhibitory Concentrations (MICs) were deter-
mined by an agar dilution method with final concentrations 
ranging from 0.025 to 32mg/l for metronidazole (Sigma, 
U.S.A.), 1 to 128mg/l PE extract, and 1 to 1024mg/l for 
CHL extract, all tested at two-fold serial increments. Heli-
cobacter pylori (84h agar culture) was suspended in ster-
ile distilled water and after adjusting turbidity to a scale of 
0.5 on the MacFarland standard (Biomerieux, France), 20 
µl was spotted onto growth medium (control) and respec-
tively onto metronidazole PE extract, CHL extract con-
taining growth media. Media used for this test was Eugon 
agar (BBL, U.S.A.) plus 10% (v/v) human blood. Incuba-
tion was at 37oC under CO2 + air atmosphere. MIC was 
defined as the lowest concentration of the antibiotic or ex-
tract tested that showed no observable bacterial growth.
Results
Chemical constituents of D. trifoliata extracts
Chemical analysis revealed that PE extract contained fat-
ty acids, steroids and triterpenoids, CHL extract contained 
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alkaloids, phenols and phenyl propanoids, while MET ex-
tract contained phenyl propanoids, tannin and mucilage.
Sensitivity of H. pylori towards the extracts
All the plants tested possessed anti H. pylori activity. Nine-
ty-eight percent of the organic solvent extracts (108/110) 
inhibited H. pylori as compared to only slightly more than 
10% (4/38) of water extracts. The 4 water extracts were 
prepared from Desmos cochinchinensis Lour. leaf, Or-
thosiphon stamineus Benth. leaf, and stem, and Psidium 
guajava L. leaf. Two plants D. cochinchinensis, and Labi-
sia pumila Benth. & Hook.f. yielded only MET extract as 
the only organic extract. These are shown on Table 2.
The amount of extract per disc was not standardized in 
the initial screening for anti-H. pylori activity. Therefore, for 
some extracts, a wide inhibition zone was only indicative 
of potential anti-H. pylori activity. This does not necessar-
ily mean stronger antibacterial activity compared to other 
extracts that exhibited smaller inhibition zones. Thus the 
ratio of inhibition zone diameter to amount of extract per 
disk was used to indicate differential strength of anti-H. 
pylori activity (Table 2, shown in parenthesis). The two 
Table 2. Inhibition of Helicobacter pylori by traditional medicinal plants from Malaysia.
Plants Part 
used




Calotropis gigantea (L.) 
W.T. Aiton
Leaf 13.2 +0.8 (11.8) 14.0 +0. 9 (12.5) 9.8 +1.2 (1.4) NZ
Centella asiatica (L.) Urb. Whole  8.5 +0.6 (7.1)  8.2 +0.4 (14.6 13.0 +0.9 (0.9) NZ
Chromolaena odorata (L.) 
R.M. King & H. Rob.
Leaf 20.3 +1.4 (8.8) 25.7 +1.0 (29.2) 25.3 +1.6 (2.8) NZ
Colubrina asiatica (L.) Brongn. Leaf 11.0 +0.9 (0.4) 10.0 +0.9 (8.3) 16.3 +2.1 (0.7) NZ
Cosmos caudatus Kunth Leaf 16.0 +0.6 (8.3) 11.7 +0.5 (29.2) 23.0 +0.9 (2.1) NZ
Cymbopogon citratus (DC.) 
Stapf
Stem 29.5 +1.5 (16.0) 18.0 +1.4 (75.0) 28.5 +1.5 (1.5) NZ
Desmos cochinchinensis Lour. Leaf NE NE 30.0 +2.1 (1.4) 10.0 +0. 6 (3.6)
Derris trifoliata Lour. Stem 42.0 +0.9 (87.5) 47.0 +1.7 (117.5) 47.0 +0.9 (5.0) NZ
Ficus deltoidea Jack Leaf 8.0 +0.1 (7.7) 10.0 +0.6 (17.9) 12.0 +0.6 (2.4) NZ
Hibiscus rosa-sinensis L. 
(white variety)
Leaf 11.5 +1.1 (24.0) 11.2 +1.2 (46.5) 14.3 +1.0 (2.1) NZ
Stem 13.2 +0.8 (5.7) 9.6 +0.6 (10.9) 13.7 +1.2 (2.7) NZ
Jatropha podagrica Hook. Leaf 13.0 +1.1 (54.2) 10.0 +0.5 (62.5) 8.0 +0.5 (6.3) NZ
Stem 15.5 +1.4 (38.8) 14.0 +0.9 (25.0) 9.2 +0.8 (0.8) NZ
Root 47.3 +3.0 (10.4) 42.0 +0.5 (27.6) 34.0 +2.5 (2.2) NZ
Kaempferia galanga L. Leaf 62.0 +0.1 (19.9) 66.0 +0.1 (63.5) 46.0 +0.1 (7.6) NZ
Tuber 18.3 +1.0 (17.6) 18.3 +1.0 (13.5) 11.0 +0.6 (1.6) NZ
Labisia pumila Benth. & Hook.f. Root NE NE  8.0 +0.5 (3.7) NZ
Languas galanga (L.) Stuntz Tuber 39.3 +2.1 (14.1) 24.2 +1.6 (18.9) 21.5 +1.9 (2.3) NZ
Limnocharis flava (L.) 
Buchenau
Leaf 24.0 +0.6 (5.5) 14.0 +0.6 (2.2) 11.0 +1.1 (0.5) NZ
Melastoma malabathricum L. 
(blue variety)
Leaf 14.0 +2.3 (6.3) 22.2 +1.3 (4.5) 25.7 +0.8 (2.0) NZ
Stem 10.5 +0.8 (16.4) 7.2 +0.4 (29.9) 18.0 +0.6 (1.6) NZ
Mimosa pudica L. Whole 8.5 +0.6 (26.6) 8.8 +1.6 (0.4) 14.2 +1.9 (2.8) NZ
Mitrasacme alsinoides R. Br. Leaf 11.0 +0.6 (2.2) 9.5 +1.1 (5.4) 13.3 +2.3 (1.0) NZ
Neptunia oleracea Lour. Leaf 10.5 +0.8 (8.2) 10.7 +2.0 (1.5) 28.3 +4.1 (1.1) NZ
Orthosiphon stamineus Benth. Leaf 17.7 +2.8 (8.5) 18.3 +2.2 (11.5) 22.0 +2.4 (4.4) 9.0 +1.3 (3.2)
Stem 12.7 +0.5 (79.2) 11.3 +1.0 (47.2) 16.0 +0.9 (4.2) 8.0 +0.1 (2.9)
Parkia speciosa Hassk. Seed 10.5 +0.8 (2.6) 26.0 +0.6 (25.0) 18.0 +0.1 (1.6) NZ
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highest values recorded were 117.5 and 87.5 exhibited by 
CHL and PE extracts of D. trifoliata respectively. The low-
est value (0.4) was exhibited by MET extract of Sesbania 
grandiflora (L.) Pers., PE extract of Centella asiatica (L.) 
Urb. and CHL extract of Mimosa pudica L. 
Sensitivity of other bacteria towards 
PE, CHL, and MET extracts
In view of their strong activity against the focal bacteria H. 
pylori, both PE and CHL extracts were further evaluated 
for their activity against thirteen other pathogenic and non 
pathogenic bacteria, representing eight genera. MET ex-
tract was also evaluated for comparison. 
Plants Part 
used




Pereskia sacharosa Griseb. Leaf 13.3 +0.5 (83.3) NZ NZ NZ
Phaeomeria imperialis (Roscoe) 
Lindl.
Flower 18.0 +1.1 (7.3) 14.0 +0.6 (10.9) 16.3 +1.4 (4.5) NZ
Phyllanthus niruri L. Whole 14.0 +1.6 (8.0) 9.8 +0.8 (11.2) 29.7 +1.4 (3.6) NZ
Piper betle L. Leaf 54.2 +0.8 (6.3) 25.8 +0.8 (4.9) 23.5 +0.8 (3.9) NZ
Pluchea indica (L.) Less. Leaf 13.7 +1.9 (5.9) 11.0 +0.6 (6.9) 23.0 +1.3(13.7) NZ
Polygonum minus Huds. Leaf 15.5 +0.6 (12.1) 12.3 +0.8 (22.0) 15.5 +1.1 (1.5) NZ
Psidium guajava L. Leaf 8.5 +0.8 (5.1) 10.0 +0.6 (3.6) 33.0 +2.3 (1.3) 7.0 +0.5 (2.5)
Sesbania grandiflora (L.) Pers. Leaf 10.8 +1.0 (2.4) 8.8 +1.3 (3.9) 17.3 +1.6 (0.4) NZ
Solarnum torvum Sw. Seed 11.0 +0.9 (17.2) 8.7 +0.8 (18.1) 12.3 +0.8 (2.2) NZ
Tinospora cordifolia (Willd.) 
Miers
Stem 10.7 + 0.8 (11.1) 19.2 + 5.0 (10.9) 13.7 + 2.7 (1.7) NZ
Zingiber officinale Roscoe Tuber 33.3 + 1.6 (10.2) 41.5 + 7.0 (7.2) 19.7 + 1.5 (1.9) NZ
Number in parenthesis indicates ratio of inhibition zone diameter: mg extract per disc. Negative control (20 µl DMSO 
incorporated per disc) gave no inhibition zone against H. pylori. NZ= not inhibited. NE=No extract produced.
Table 3. Inhibitory activity of Derris trifoliata Lour. against Helicobacter pylori and other common pathogenic and non 
pathogenic bacteria by disc diffusion assay.
Bacteria tested Diameter* of zone of inhibition (mm) produced
PE extract CHL extract MET extract
Enterobacter sp. NZ NZ 8.0+0.1
Escherichia coli ATCC 25922 NZ NZ 15.0+1.0
Escherichia coli NZ NZ 8.0+0.1
Proteus vulgaris NZ NZ 12.7+0.6
Pseudomonas aeruginosa 7.3+0.6 14.0+1.0 11.3+1.0
Pseudomonas stutzeri NZ 7.0+0.1 NZ
Salmonella paratyphi A NZ 7.0+0.5 NZ
Salmonella sp. NZ NI 13+1.0
Shigella boydii NZ 7.0+0.1 NZ
Shigella dysenteriae NZ 7.0+0.1 NZ
Staphylococcus aureus NZ NZ 7.0+0.1
Vibrio cholerae 6.5+0.1 6.5+0.1 NZ
Vibrio parahaemolyticus NZ 7.0+0.1 NZ
Helicobacter pylori SJ47 42.0+1.0 38.0+1.0 8.5+1.0
*mean of three values; NZ= not inhibited. 
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Petroleum ether extract inhibited Pseudomonas aerugi-
nosa and Vibrio cholerae but inhibitory effect based on 
inhibition diameter was significantly smaller (6.5 – 7.3mm) 
compared to H. pylori (42mm)(Table 3). CHL inhibited a 
wider range of bacteria; Vibrio parahaemolyticus, V. chol-
erae, S. paratyphi A, S. boydii, S. dysenteriae, and P. 
stutzer. It is worthy of note that the inhibitory activity was 
also smaller (6.5-7.0mm) compared to that for H. pylori 
(38mm). MET inhibited a wide range of bacteria but it was 
relatively inactive against H. pylori exhibiting only 8.5mm 
inhibition zone diameter compared to 11 to 15mm against 
E. coli ATTC 25922, Salmonella sp and Pseudomonas sp. 
Of the three extracts tested, MET extract was least active 
against H. pylori. 
Toxicity of the extracts on Artemia salina
Toxicity tests were carried out in triplicates using A. salina. 
Using the formula given in section 2.6, PE extracts proved 
to be the most toxic of the D. trifoliata extracts tested LC50 
= 1.4 µg/ml, followed by CHL extract (1.1 µg/ml) and MET 
extract (54.9 µg/ml). These are shown on Table 4.
Table 4. Toxicity of extracts of Derris trifoliata Lour. against Artemia salina Leach.
Log conc. of 
extract (µg/ml)

















2.107 32 32 100 29 29 100 32 26 81.25
1.806 36 36 100 34 34 100 31 19 61.29
1.505 32 32 100 40 40 100 30 3 10.00
1.204 30 30 100 45 45 100 32 1 3.13
0.903 38 34 89.47 41 41 100 32 0 0
0.602 33 23 69.70 51 46 90.20 34 0 0
0.301 31 19 61.29 48 32 66.67 34 0 0
0.001 40 16 40.00 54 26 48.15 31 0 0
LC50 D. trifoliata PE extract = 1.4 μg/ml; LC50 D. trifoliata CHL extract = 1.1 μg/ml; LC50 D. trifoliata MET extract = 54.9 
μg/ml.
MIC of PE and CHL extracts on H. pylori
Considering their narrow spectrum of activity, PE and CHL 
extracts of D. trifoliata were selected for MIC determina-
tion. Agar dilution method was used to determine the sen-
sitivity of the 47 clinical isolates of H. pylori to Metronida-
zole, PE and CHL extracts of D. trifoliata. Table 5 shows 
the sources of and clinical isolates used for the determina-
tion of MIC. Only SJ 47 and SJ 779 were metronidazole 
susceptible (MIC = 0.5 and 8.0 mg/l respectively). The 
other isolates had MIC values >8mg/l and were consid-
ered as metronidazole-resistant (Goh et al. 2000).
Fifteen clinical isolates (SJ 1, 2, 6-13, 17-19, 26 and 32) 
were used for the determination of MIC against PE ex-
tract. SJ 95 and SJ 155 were subsequently lost and there-
fore only the remaining 45 isolates were used for MIC de-
termination against CHL extract.
Table 5. Source of, and minimum inhibitory concentration (MIC) of metronidazole (Metron), Petroleum Ether (PE), 
and Chloroform (CHL) extracts of Derris trifoliata Lour. against clinical isolates of Helicobacter pylori. NR = no report, 
ND = not done, DN = duodenitis, PPU = prepyloric ulcer, PG = pyloric gastritis, DU=duodenal ulcer, NUD = non-ulcer 
dyspepsia, AG= antral gastritis, M=Malay, C = Chinese, I = Indian, ML = male, F = female




1. SJ 46 M ML 50 AG >32 2 2
2. SJ 47 I F 60 AG 0.5 2 2
3. SJ 65 C F 46 AG >32 ND 2
4. SJ 69 C F 70 NUD >32 ND 2
5. SJ 70 C F 63 NUD >32 ND 2
6. SJ 77 M ML 24 AG >32 1 1
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7. SJ 95 C F 68 AG >32 1 ND
8. SJ 98 C ML 69 DU >32 1 1
9. SJ 109 I ML 47 AG >32 2 2
10. SJ 115 C ML 26 AG >32 2 2
11. SJ 136 I ML 37 DU >32 4 4
12. SJ 137 I ML 33 AG >32 4 4
13. SJ 143 C ML 45 AG >32 1 2
14. SJ 147 I ML 40 NUD >32 ND 2
15. SJ 148 I ML 45 AG >32 ND 4
16. SJ 152 I ML 56 PPU >32 ND 4
17. SJ 153 C ML 67 PPU 32 1 1
18. SJ 154 C ML 42 PPU >32 1 1
19. SJ 155 M ML 34 DU >32 1 ND
20. SJ 157 C ML 70 AG 32 ND 4
21. SJ 160 I ML 60 AG >32 ND 2
22. SJ 164 C ML 51 AG >32 ND 2
23. SJ 175 B ML 30 AG >32 ND 8
24. SJ 179 I ML 30 AG >32 ND 4
25. SJ 184 I ML 41 PG >32 ND 4
26. SJ 185 I ML 46 AG >32 1 1
27. SJ 195 C ML 67 NR >32 ND 4
28. SJ 198 C ML 37 AG >32 ND 2
29. SJ 205 I F 55 AG >32 ND 2
30. SJ 248 B ML 47 NUD >32 ND 2
31. SJ 251 M ML 45 AG >32 ND 2
32. SJ 255 I ML 60 AG >32 1 1
33. SJ 270 I ML 42 AG >32 ND 1
34. SJ 295 B ML 25 NUD >32 ND 1
35. SJ 300 C F 55 AG >32 ND 1
36. SJ 334 M ML 38 AG >32 ND 1
37. SJ 371 C ML 45 DU >32 ND 4
38. SJ 381 M ML 45 AG 32 ND 1
39. SJ 392 I ML 48 PPU >32 ND 8
40. SJ 393 I F 45 NUD >32 ND 4
41. SJ 422 I F 48 AG >32 ND 1
42. SJ 443 I ML 60 AG >32 ND 1
43. SJ 452 B ML 32 AG >32 ND 4
44. SJ 779 B ML 43 DN 8 ND 4
45. SJ 808 C ML 62 DU >32 ND 4
46. SJ 815 M ML 70 DN 32 ND 1
47. SJ 885 I ML 56 DN >32 ND 4
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Using PE extract, 60% 0f the isolates were inhibited by 
1mg/l, 87% by 2mg/l and 100% by 4mg/l. The isolate SJ 
47 which was sensitive to metronidazole was inhibited by 
PE extract at 2mg/l. MIC50 and MIC90 was about 1mg/l and 
2mg/l respectively.
Using the CHL extract, 64% of the isolates were inhibited 
by 2mg/l, 95.6% by 4mg/l and 100% by 8mg/l. The iso-
lates SJ 47 and SJ 779 were killed by complete inhibition 
by I and 2mg/l respectively. MIC50 and MIC90 of CHL ex-
tract was about 2 and 4mg/l respectively.
Discussion and conclusion
H. pylori resistance to antibiotics is a world wide problem. 
Our primary objective was to evaluate in-vitro activity of 
32 ethnobotanical Malaysian plants used for the treatment 
of abdominal ailments, especially D. trifoliata for anti-clin-
ical H. pylori activities.
Successful treatment of H. pylori infections is dependent 
on the antibacterial susceptibility pattern of the organism 
and patient compliance (Osato et al. 1999). The increas-
ing resistance of H. pylori strains to metronidazole, one of 
the primary drugs of choice (used in combination) for the 
treatment of H. pylori infection is of great concern espe-
cially in tropical and developing countries. Reduced suc-
cess rates of current therapies have been reported and a 
correlation made between metronidazole and treatment 
failure (Jenks & Edwards 2002).
The prevalence of H. pylori resistant to metronidazole re-
ported in this study (95.7%) is alarmingly high. This value 
is comparatively higher than values obtained in other de-
veloping countries (Ani et al.1999, Mégraud 2001, Osato 
et al. 1999, Ragab et al. 2009, Rahman et al. 2009).This 
might be as a result of the use of this agent for the treat-
ment of genitourinary infections and other parasitic infec-
tions. It could also have arisen as a result of abuse of 
this drug owing to illegal practices and poor compliance 
with pharmaceutical regulations. This study also revealed 
a lower occurrence of metronidazole resistance in strains 
of H. pylori isolated from females (88.89%) compared with 
those isolated from males (97.39%). Other studies have 
often showed higher frequencies of metronidazole resis-
tance from females, (Osato et al. 1999). Our data howev-
er may have been skewed owing to the small number of 
females available for analysis. 
Although all the plants tested in this study possessed an-
ti-H. pylori activities, the index of their activities varied. 
One limitation was that the tests were performed on crude 
extracts without isolating and testing the pure bioactive 
compounds. As such, it may not be known if the biological 
action (inhibitory and (or) toxic) is due to one or several 
compounds. Lai et al. (2008) agreed that the isolation of 
pure compounds does not necessarily lead to an increase 
in H. pylori inhibition as expected, with Phyllanthus urinaria 
L. Given that limitation, the PE extract of D. trifoliata con-
tained fatty acids, and tripenoids, a class of compounds 
that has previously been reported to be inhibitory to H. 
pylori (Murphy Cowan 1999, Gadhi et al. 2001, Petschow 
et al. 1996). The CHL extract of that same plant contained 
alkaloids, another group of compounds known to have 
members specifically inhibitory to H. pylori (Hamasaki et 
al. 2000, Klausmeyer et al. 2004). The fact that PE and 
CHL extracts of D. trifoliata exhibited strong in-vitro anti-H. 
pylori activity and relatively ineffective against other com-
mon bacteria tested suggest the presence of compounds 
possessing more selective and specific action against H. 
pylori. Therefore, given the age long traditional use of this 
plant in Malaysia, further investigation of these two ex-
tracts is indicated. 
MIC values in this study were determined for PE and 
CHL extracts. These were favored because of their nar-
rower antibacterial spectrum of activity. Our findings show 
that MIC values for the extracts ranged from 1-4 µg/ml. 
These values are higher than therapeutically acceptable 
for many antibiotics used in H. pylori eradication. How-
ever, they are lower than values suggested for metronida-
zole, tetracycline, rifampin and tinidazole. (McDermott et 
al. 2009). McDermott et al. (2009) in their review suggest-
ed interpretative breakpoints for the most common antibi-
otics used in the treatment of H. pylori induced gastritis. 
Their suggested susceptible MIC values for therapy with 
amoxicillin, ciprofloxacin, clarithromycin, levofloxacin, and 
mixifloxacin is <1µg/ml, for furazolidone, nitrofurantoin 
is <2µg/ml, for rifampin is 4µg/ml, for tinidazole, metron-
idazole is <8µg/ml, and tetracycline is <16µg/ml. These 
values corroborate therapeutically effective susceptibility 
values reported for eradication of H. pylori (Okabe et al. 
1997). It is worthy of note that MIC of PE extract reported 
in this work is at least 4 times lower, compared to MIC 
values found in literature for several anti H. pylori extracts 
from plant sources (Castillo-Juárez et al. 2009, Cellini et 
al. 2001, Chinniah et al. 2009, Fabry et al. 1996, Ingolfs-
dottir et al. 1997, Jones et al. 1997, Li et al. 2005, Mabe et 
al. 1999, Tabak et al. 1999). This makes this plant eligible 
for further studies. Though the extracts were effective at 
low concentrations, LC50 at 1.4µg/ml indicated toxicity at 
the concentration inhibitory to most H. pylori tested. This 
may undermine its usefulness. Toxicity of samples has 
been shown to be dependent on the concentration of spe-
cific compound(s) in the sample (Svensson et al. 2005). 
They, also showed that in some impure complicated sam-
ples, the data obtained by a biologist may be more diffuse. 
The level of toxicity observed in this study may have re-
sulted from presence of multiple compounds in the crude 
extracts, acting in synergy or independently. Thus, isola-
tion and testing of the pure anti-H. pylori component, may 
produce lower levels of toxicity. 
Among the extracts tested, PE extract showed the wid-
est diameter zone of inhibition (42mm). This extract also 
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interestingly possessed activity against P. aeruginosa and 
V. cholerae which are gastro intestinal pathogens, but 
showed no activity against E. coli and other normal micro-
flora of the gastro intestinal tract. This finding raises hope 
for the possibility of developing an antibacterial agent 
from this extract that can exhibit selective and specific in-
hibitory action against V. cholerae and H. pylori without 
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